L R A Lepelaars

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND Biosimilars have been available in the European Union since 2006. However, their uptake in routine care is heterogeneous across countries. AIMS To compare the safety information of biosimilars and their originators based on the information in the EU risk management plan (RMP). METHODS A cross-sectional analysis on publicly available(More)
  • 1